ANXA1 binds to macrophages’ FPR2, promoting TAMs polarization towards the immunosuppressive M2 phenotype in TME, by activating the PI3K/AKT and ERK1/2 pathways, leading to tumor progression stimulation by increasing cancer cell resistance to immune-mediated therapies [38,141,183]. This evidence concerns the gene ANXA1 and neoplasm.